| Cytokine release syndrome: current perspectives H Murthy, M Iqbal, JC Chavez, MA Kharfan-Dabaja ImmunoTargets and therapy, 43-52, 2019 | 146 | 2019 |
| Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission A Rashidi, M Hamadani, MJ Zhang, HL Wang, H Abdel-Azim, M Aljurf, ... Blood advances 3 (12), 1826-1836, 2019 | 106 | 2019 |
| Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity conditioning transplant … S Ahmed, JA Kanakry, KW Ahn, C Litovich, H Abdel-Azim, M Aljurf, ... Biology of blood and marrow transplantation 25 (9), 1859-1868, 2019 | 59 | 2019 |
| Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma PN Munshi, D Vesole, A Jurczyszyn, JM Zaucha, A St. Martin, O Davila, ... Cancer 126 (23), 5077-5087, 2020 | 55 | 2020 |
| Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia MJ Wieduwilt, L Metheny III, MJ Zhang, HL Wang, N Estrada-Merly, ... Blood advances 6 (1), 339-357, 2022 | 48 | 2022 |
| Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs … GSG Murthy, S Kim, ZH Hu, N Estrada-Merly, MB Abid, M Aljurf, U Bacher, ... JAMA oncology 8 (3), 404-411, 2022 | 43 | 2022 |
| Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide A Im, A Rashidi, T Wang, M Hemmer, ML MacMillan, J Pidala, M Jagasia, ... Biology of blood and marrow transplantation 26 (8), 1459-1468, 2020 | 42 | 2020 |
| Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant N Ghosh, S Ahmed, KW Ahn, M Khanal, C Litovich, M Aljurf, VU Bacher, ... JAMA oncology 6 (7), 1011-1018, 2020 | 42 | 2020 |
| Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta … MA Kharfan-Dabaja, T Reljic, HS Murthy, E Ayala, A Kumar Clinical Lymphoma Myeloma and Leukemia 18 (11), 703-709. e1, 2018 | 37 | 2018 |
| Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis M Iqbal, T Reljic, E Ayala, T Sher, H Murthy, V Roy, J Foran, H Tun, ... Biology of Blood and Marrow Transplantation 26 (1), 76-82, 2020 | 35 | 2020 |
| Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis NN Shah, KW Ahn, C Litovich, TS Fenske, S Ahmed, M Battiwalla, ... Blood advances 2 (8), 933-940, 2018 | 34 | 2018 |
| Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials F Yassine, M Iqbal, H Murthy, MA Kharfan-Dabaja, JC Chavez Current Research in Translational Medicine 68 (4), 159-170, 2020 | 33 | 2020 |
| Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma … N Epperla, KW Ahn, C Litovich, S Ahmed, M Battiwalla, JB Cohen, P Dahi, ... Journal of Hematology & Oncology 12, 1-11, 2019 | 33 | 2019 |
| Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? O Saifi, WG Breen, SC Lester, WG Rule, B Stish, A Rosenthal, J Munoz, ... Radiotherapy and Oncology 166, 171-179, 2022 | 32 | 2022 |
| Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis R Bishnoi, Z Xie, C Shah, J Bian, HS Murthy, JR Wingard, N Farhadfar Cancer medicine 10 (1), 70-78, 2021 | 32 | 2021 |
| Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era B Dhakal, S Patel, S Girnius, L Bachegowda, R Fraser, O Davila, ... Leukemia 34 (12), 3338-3347, 2020 | 32 | 2020 |
| Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation M Joshi, J Cook, K McCullough, A Nanaa, N Gangat, JM Foran, ... Blood cancer journal 11 (3), 49, 2021 | 30 | 2021 |
| Frailty: the missing piece of the pre-hematopoietic cell transplantation assessment? A Hegde, HS Murthy Bone Marrow Transplantation 53 (1), 3-10, 2018 | 30 | 2018 |
| The effect of donor graft cryopreservation on allogeneic hematopoietic cell transplantation outcomes: a Center for International Blood and Marrow Transplant Research analysis … JW Hsu, N Farhadfar, H Murthy, BR Logan, S Bo-Subait, N Frey, ... Transplantation and cellular therapy 27 (6), 507-516, 2021 | 29 | 2021 |
| Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid … M Norkin, L Katragadda, F Zou, S Xiong, M Chang, Y Dai, JW Hsu, ... Blood Cancer Journal 7 (12), 634, 2017 | 29 | 2017 |
Nosha FarhadfarAssistant professor of Medicine, University of FloridaVerified email at medicine.ufl.edu
